Ignite Creation Date:
2025-12-24 @ 11:55 PM
Ignite Modification Date:
2026-02-01 @ 6:18 PM
Study NCT ID:
NCT06366451
Status:
RECRUITING
Last Update Posted:
2025-01-20
First Post:
2024-04-03
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
Sponsor:
Presage Biosciences
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Head and Neck Squamous Cell Carcinoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | HNSCC | View |
| None | intratumoral microdosing | View |
| None | microdose injection | View |
| None | microdosing | View |
| None | in vivo oncology | View |
| None | tumor microenvironment | View |
| None | multiplexed immunohistochemistry | View |
| None | head and neck cancer | View |
| None | head and neck squamous cell carcinoma | View |
| None | pharmacodynamic biomarkers | View |
| None | CIVO | View |
| None | master protocol | View |
| None | precision oncology | View |
| None | spatial biology | View |